The "love hormone" — endogenous bonding peptide also prescribed as Pitocin for labor induction, and used off-label for social connection, orgasm intensity, and mood.
Oxytocin is a nine-amino-acid neuropeptide produced in the hypothalamus and released by the posterior pituitary. It governs uterine contraction during labor, milk ejection during breastfeeding, and — most relevantly for peptide therapy use — social bonding, trust, empathy, and orgasm.
The FDA-approved pharmaceutical form, Pitocin, is used for labor induction and postpartum hemorrhage control. Off-label use for social / sexual / mood applications typically involves intranasal delivery (crosses the blood-brain barrier better than injection) or SubQ.
Pharmaceutical oxytocin (Pitocin) FDA approved for specific indications. Not WADA prohibited. Off-label / research-peptide use is common.
Binds oxytocin receptors in the brain (hypothalamus, amygdala, nucleus accumbens) and peripheral tissues. Central effects drive the bonding / trust / empathy changes; peripheral drives contraction.
Oxytocin does not cross the blood–brain barrier well from the bloodstream, so injections produce mainly peripheral effects. Intranasal delivery is proposed to reach the brain via olfactory and trigeminal pathways, and nearly all bonding research uses that route.
How well it actually works is disputed by the physiologists who study it. Leng and Ludwig (PMID 26049207) reviewed the delivery evidence and concluded that "very little of the huge amounts applied intranasally appears to reach the cerebrospinal fluid," while peripheral concentrations rise to supraphysiologic levels with likely effects on the gastrointestinal tract, heart and reproductive tract. Their warning is blunt: "the wish to believe in the effectiveness of intranasal oxytocin appears to be widespread and needs to be guarded against with scepticism and rigor."
Two consequences. The central effects may be smaller than the literature implies, and the dose you spray is mostly going somewhere other than your brain — which makes the peripheral cautions in the safety section more relevant, not less.
Plasma half-life ~3–5 minutes. Effects from a dose are functionally ~30–60 min in CNS depending on delivery route.
| Benefit | Evidence |
|---|---|
| Labor induction (Pitocin) | Gold-standard clinical use; FDA approved |
| Social bonding / trust | The famous finding did not replicate. Kosfeld 2005 launched a decade of trust-game research; the critical review of that literature (Nave 2015, PMID 26581735) concludes "the simplest promising finding associating intranasal OT with higher trust has not replicated well," that plasma-oxytocin evidence is compromised by measurement problems, and that large-sample genetic studies found no consistent association. Their verdict: the cumulative evidence "does not provide robust convergent evidence that human trust is reliably associated with OT (or caused by it)" |
| Orgasm intensity | Small studies only, and worth reading against the delivery problem below — peripheral oxytocin receptors in reproductive tissue are reached far more reliably than central ones, so a genital effect does not establish a brain effect |
| Autism spectrum | The largest trial was clearly negative. SOARS-B (Sikich 2021, NEJM, PMID 34644471) randomised 290 children and adolescents to 48 IU/day intranasal oxytocin or placebo for 24 weeks. Change in the primary social-withdrawal measure was −3.7 on oxytocin versus −3.5 on placebo (difference −0.2, 95% CI −1.5 to 1.0, p = 0.61), with secondary outcomes generally no different |
| Breastfeeding support | Prescribed in some settings, but the trial evidence is negative. In a randomised double-blind study of 51 mothers expressing milk for preterm infants (Fewtrell 2006, PMID 16223754), total milk production did not differ from placebo, and most mothers believed they were on the active spray — the authors attribute the apparent benefit to placebo effect and the extra breastfeeding support provided during the study |
| Anxiety / depression | Mixed but intriguing; studied in social anxiety disorder |
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeNot medical advice. These figures describe what is reported in the literature and what practitioners and communities do — not a recommendation, and for most compounds here no human dose-finding study exists. Talk to a qualified healthcare provider.
SubQ produces mainly peripheral effects; for central bonding / mood effects, intranasal is preferred.
Research-chem oxytocin is often supplied as milligrams; pharmaceutical forms use IU. Typical conversion: 1 mg = ~500 IU of oxytocin activity. Always confirm your specific product’s concentration.
Not medical advice. These figures describe what is reported in the literature and what practitioners and communities do — not a recommendation, and for most compounds here no human dose-finding study exists. Talk to a qualified healthcare provider.
2 mg vial + 5 mL saline = 400 mcg/mL (~200 IU/mL). Standard pump delivers ~100 µL (0.1 mL) = 40 mcg per spray (~20 IU). 1–2 sprays for typical dose.
Pre-filled with a typical Oxytocin setup. Edit any field — the draw updates live.
Insulin syringe — 100 units = 1 mL
Free account. Saves your reconstitution + schedules doses + tracks every vial.
Dosing cheat sheet, reconstitution reference, and cycle planning — delivered to your inbox.
Oxytocin is a research peptide not approved by the FDA for human use. It is sold only as a research chemical, and StackTrax does not endorse or facilitate personal use.
Quality varies enormously among research-chemical suppliers. At minimum, look for:
Lyvn does not carry Oxytocin. They are the vendor we recommend elsewhere on this site, and they publish the full independent panel per batch — which makes their catalogue a useful yardstick for the criteria above even on a compound they do not stock. We are not recommending a specific supplier for Oxytocin itself, because we have no basis to.
For research use only. Not for human consumption. 21+.
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeYes, but only as Pitocin for specific obstetric indications: labor induction and postpartum hemorrhage control. Off-label use for social bonding, sexual, or mood applications is not FDA approved and typically involves intranasal delivery or subcutaneous injection through compounding pharmacies or the research-chemical market. Oxytocin is not WADA prohibited.
Oxytocin does not cross the blood-brain barrier well from the bloodstream, so injections produce mainly peripheral effects. Intranasal delivery is proposed to reach the brain via olfactory and trigeminal pathways, which is why bonding research uses that route — but how much actually arrives is disputed. Leng and Ludwig (PMID 26049207) found very little of an intranasal dose appears to reach cerebrospinal fluid, while peripheral levels rise to supraphysiologic concentrations affecting the gut, heart and reproductive tract.
The Kosfeld 2005 Nature study and follow-ups show real but modest effects on social bonding and trust. Intranasal oxytocin before sexual activity has also been reported to enhance orgasm in small studies. Effects are not dramatic and oxytocin can intensify current mood in either direction, not just positive.
The evidence is mixed. The SOARS-B Phase 2 trial was negative for social communication improvement in autism spectrum disorder, while smaller studies have been more positive. Mixed results overall, with no clear consensus on whether intranasal oxytocin produces clinically meaningful benefit in this population.
Intranasal is the most common off-label route at 10 to 40 IU (roughly 20 to 80 mcg), PRN or once daily, 30 to 45 minutes before the desired effect. Subcutaneous dosing is 2 to 10 IU, but this mainly produces peripheral effects. The plasma half-life is about 3 to 5 minutes, with functional CNS effects lasting roughly 30 to 60 minutes depending on route.
Common mild effects include nasal irritation (intranasal), mild headache, transient nausea, and mood changes that are not always positive since oxytocin can intensify current mood in either direction. Less common effects include water retention at higher doses (antidiuretic effect), flushing, and mild blood pressure increases.
Do not use oxytocin in pregnancy (unless under obstetric care for labor induction), with hyponatremia risk from excess water intake, or with known hypersensitivity to oxytocin. Use caution with cardiovascular disease, uncontrolled blood pressure, and psychiatric conditions where mood intensification could be harmful.
Disclaimer: This guide is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The compounds discussed are not FDA approved for human use. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol. StackTrax does not sell peptides or supplements directly — purchase links go to third-party vendors. StackTrax is not responsible for the products, quality, or business practices of any third-party vendor.
© 2026 StackTrax, LLC. All rights reserved.
Privacy · Terms · Do Not Sell or Share My Personal Information
StackTrax guides cover peptides and compounds that are not FDA-approved for the uses discussed. The dosing, reconstitution, and safety information is compiled from published research and community protocols for educational purposes only.
Before using any compound mentioned here, consult a qualified healthcare provider. StackTrax does not sell, prescribe, or recommend these substances for personal use.